In January 2026, I had the opportunity to begin the new year in a different academic environment through a one-month secondment at the Medical University of Vienna (MUW).
Read More
Some cancers, like anaplastic large-cell lymphoma (ALCL), are driven by a gene called ALK that gets rearranged, causing cancer cells to receive signals to grow more than they should.
Read More
During my stay at MLL, I had the opportunity to attend the MLL MVZ Innovation Summit 2025, where I gained insights into the latest NGS technologies and single-cell sequencing applications
Read More
As part of the FANTOM Doctoral Network, I completed my three-month secondment at the Medical University of Vienna in the lab of Prof. Gerda Egger, an internationally recognized group with strong expertise in cancer epigenetics.
Read More
Cancer is one of the most common and serious diseases worldwide. In terms of mortality, it is the second leading cause of death, just behind cardiovascular disease. Education and prevention are fundamental to the fight against cancer.
Read More
The FANTOM project (Future of ALCL: Novel Therapies, Origins, Biomarkers and Mechanisms of Resistance) is a prestigious international network funded under the Marie Skłodowska-Curie Actions – Doctoral Networks (MSCA DN).
Read More
New applications of sustainable, scalable, standardized, and cost-effective human biomaterials for cell-based assays, tissue engineering, and regenerative medicine.
Read More
From June to September 2025, I completed a secondment at the Division of Cellular and Molecular Pathology, University of Cambridge, United Kingdom
Read More
FANTOM students recently took part in the first in-person conference of the Young NHL Network (yNHL), held at Queens’ College, University of Cambridge in October 2025.
Read More
FANTOM Students Present at International Non-Hodgkin Lymphoma Symposium in New York
Read More